LifeStance Health Group, Inc. Q2 FY2025 earnings call

• Clinician base expanded by 173 in the quarter, reaching 7,780 total. - Implemented a clinician cash incentive program in May, a patient engagement platform, and enhanced Care Matching capabilities. - Leveraged AI tools for revenue cycle processes, patient scheduling, and clinician documentation. - Appointed Vaughn Paunovich as Chief Technology Officer to lead technology enablement, including AI and digital solutions.

Revenue grew 11% year-over-year to $345 million. Visit volumes of $2.2 million increased 12% year-over-year. Clinician base grew by 173 to 7,780. Center margin was $108 million, up 11% year-over-year and 31.4% of revenue. Adjusted EBITDA was $34 million, up 19% year-over-year, 9.8% of revenue. Free cash flow was $57 million, the highest in LifeStance's history. Revenue contribution breakdown: Revenue growth driven by clinician growth and slightly better productivity; center margin outperformance due to revenue beat and clinician incentive program expense; adjusted EBITDA exceeded expectations due to favorable center margin and lower G&A spending.

• Raised full-year adjusted EBITDA guidance, expecting double-digit margins. - Maintained revenue guidance at $1.4 billion to $1.44 billion. - Raised center margin guidance to $441 million to $465 million and adjusted EBITDA guidance to $140 million to $150 million. - Q3 revenue expected $345 million to $365 million, center margin $105 million to $119 million, and adjusted EBITDA $33 million to $39 million. - Anticipates mid-teens revenue growth in 2026 with expanding margins, expecting low to mid-single-digit rate improvement and continued clinician base growth.

• Regulatory risks related to the evolving use of AI in therapy sessions. - Payers potentially reining in mental health cost trends, though not a new dynamic. - Competitive landscape in clinician recruiting and retention, which remains highly competitive.

Q: Just a question on the implied ramp for Q4. And I appreciate all the color in the prepared remarks, but you should probably have some improvement from as the payer reduction headwind abates and you talked about productivity. So just looking for kind of your confidence level into that back half ramp and things that you're seeing in the business that builds that.

A: Perfect. This is Ryan. I appreciate the question. So going to the point of your question, we're super pleased with our performance in the first half for the year, and we have meaningful momentum going into the second half of the year, driving up a step-up in revenue as you kind of acknowledged in your question. In addition to revenue contribution from clinician rate, we continue to plan to drive productivity in the second half of the year. So to help to mention this, from the first half to the second half, we expect roughly $60 million of revenue growth and the way you can think about that is driven by 10% from rate and 90% from visit volume. And so kind of further to mention that, when you think of 90% that's related to visit volume, you can think of that as approximately 60% is coming from clinician ads and then 40% is coming from productivity. As we mentioned in previous quarters and our prepared comments, we're prioritizing filling existing clinician calendars, which we believe will result in increased productivity in the second half. Dave went through a number of initiatives that we have in place to drive the filling of the schedules in his prepared comments. And then to your question, just in terms of Q3 versus Q4, clinician ads will be a meaningful driver in both quarters. When you get to Q4, you will see a higher contribution for productivity as the initiatives that are in play have more time to make a meaningful impact. And then from a rate perspective, going to that part of your question, we expect modest growth in rates in first half to second half. And it really is driven by further rate negotiations with some specialty services in there. So then overall, we've absorbed the one unique payer dynamic. And so overall, we're still guiding to flat TRPV for the year. But as you get into future years, we expect to return to low to mid-single digits from a rate perspective. So to close the comments on here, we feel really good about our growth in the first half and the momentum going into the second half.

Q: I just wanted to go back to a couple of things. One, on your comment, Ryan, I think that you made around cash pay shifting towards commercial. Do you have any updates on managed care contracting, contracting around that. And just curious, is it that we're seeing expansion of the benefit that that comment was made around what you're seeing for cash pay going into the commercial volumes?

A: Lisa, it's Dave. I'll take that one. So in Ryan's remarks about the tailwinds that we're seeing in the industry, and we expect to see as we step into '26, '27, there were two things you referenced. The first was increasing demand overall for mental health services. And the second, which is what you're referencing, is a shift from cash pay to insurance. And the point we're making there is that you still have a very high percentage of clinicians today who do not accept insurance. And that is a financial challenge, makes it less affordable for patients. And so what we've seen in recent years and we expect to see in coming years is further migration of the patients from a cash pay environment to using their insurance. And obviously, that trend would benefit LifeStance as we focus on patients that have insurance.

Q: I wanted to follow up on the first question around implied guidance for 4Q. I think if we take the midpoint of 3Q and the full year, that implies about 19% revenue growth in the fourth quarter. You said about 90% of that is coming from volume, so high teens volume growth. Can you just comment on sort of the sustainability of that? And you mentioned some of the productivity initiatives you're putting in place that support the ramp to that type of volume growth exiting the year. Can you just spend a minute on what those are and your assumptions around how those initiatives translate into the improved volume growth?

A: Yes. Sure, Jamie. So this is Ryan. I'll start off, and then Dave will provide a little bit more color in terms of some of the initiatives that we're doing in totality. So you got the quantum right, in terms of -- if you kind of go back and kind of think of the progression of revenue, revenue grew Q1 to Q2 by $12 million, Q2 to Q3 we're expecting $10 million and then from Q3 to Q4 we're expecting roughly $30 million. And the way I kind of have you think about that -- similar to my second half, first half commentary is think about 75% to 80% is coming from clinician ads and productivity and roughly split for that 70%, 80%, 50-50 to productivity. So as you kind of put in your question, we've got a number of initiatives in play, both around the incentive program that we put in, Care Matching, better just practice operation type stuff that really impacts the ability to get folks filled into the clinician schedule. And so we're pleased with the progress that we've shown today. We had productivity improvement Q2 over Q2 of last year. And so we like the momentum that we're seeing around productivity and then the initiatives kind of ramping up and taking hold through Q3 into Q4. So Dave, I don't know if there's anything further you want to put on the initiatives.

Q: Last quarter, you introduced the idea of potentially starting the M&A engine again. You didn't do any this quarter it appears. But can you maybe talk about where you stand with that, how valuations are now or opportunities are now compared to when you were doing them years ago? How -- what the pipeline looks like?

A: Kevin, it's Dave. Thanks for the question. We did signal that in the last quarter, and we are active in exploring M&A. Our focus right now is primarily tuck-in acquisitions in geographies that are new to us or where we're very subscale. So this is really more of a beachhead and for geographic expansion, that's -- those opportunities are really exciting to us, whether that's entering a new MSA and a new state. So -- that's the focus. The pipeline is pretty robust, and we are actively working through a number of opportunities, but I wouldn't signal at this point timing on when you'll see those coming through. But again, that is a big focus area for us and there's a lot of positive activity there.